Samsung
Bioepis seeks Europe approval for its
Humira copy
SEOUL (Reuters) - Biosimilars maker
Samsung Bioepis, part of South Korea's top family-run conglomerate
Samsung Group [SAGR.UL], said on Monday it is seeking regulatory
approval in
Europe to sell its
copy of AbbVie Inc's rheumatoid arthritis drug Humira.
